Christopher Lock, MD, spoke with Healio about findings from the Evoke and Evoke+ trials presented at the 2026 American Academy of Neurology Annual Meeting.
May 19, 2026
1 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ECO 2026: indirect comparison favours Wegovy pill over Foundayo - Pharmaceutical Technology
Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast
Biogen pushing tau drug forward despite Alzheimer’s study failure
GLP-1s vs Bariatric Surgery; Obesity Trends Reversing; Creatine for Menopause?
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Candel reports prostate cancer drug's long-term data ahead of FDA filing
The Oral GLP-1 Tracker: Wegovy pill total scripts down for first time
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
